High-Density Lipoprotein Metabolism

  • H. Bryan BrewerJr


High-density lipoprotein (HDL) cholesterol (HDL-C) concentrations are inversely associated with coronary heart disease (CHD) in humans [1,2]. The initial descriptions of this inverse relationship in the early 1950s [3–5] were “rediscovered” in the 1970s [6–9]. The major mechanism proposed for the protective effect of HDL is reverse cholesterol transport, a process in which excess cholesterol from peripheral cells is transported back to the liver for removal from the body [10]. The higher the plasma levels of HDL, the more efficient is the transport to the liver of excess cholesterol from peripheral cells.


Reverse Cholesterol Transport Peripheral Cell Cholesterol Acyltransferase Excess Cholesterol Tangier Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gordon DJ, Probstfield JL, Garrison RJ, et al: High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989, 79:8–15.PubMedGoogle Scholar
  2. 2.
    Gordon DJ, Rifkind BM: High-density lipoprotein: the clinical implications of recent studies. N Engl J Med 1989, 321:1311–1316.CrossRefPubMedGoogle Scholar
  3. 3.
    Gofman JW, Lindgren F, Elliot H, et al: The role of lipids and lipoproteins in atherosclerosis. Science 1950, 111:166–186.CrossRefPubMedGoogle Scholar
  4. 4.
    Gofman JW, deLalla O, Glazier F, et al: The serum lipid transport system in health, metabolic disorders, atherosclerosis, and coronary artery disease. Plasma 1954, 2:413–484.Google Scholar
  5. 5.
    Barr DP, Russ EM, Eder HA: Protein-lipid relationship in human plasma. II. In atherosclerosis and related conditions. Am J Med 1951, 11:480–493.CrossRefPubMedGoogle Scholar
  6. 6.
    Miller GJ, Miller NE: Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975, 1:16–19.CrossRefPubMedGoogle Scholar
  7. 7.
    Rhoads GG, Gulbrandsen CL, Kagan A: Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med 1976, 294:293–298.CrossRefPubMedGoogle Scholar
  8. 8.
    Gordon T, Castelli WP, Hjortland MC, et al: High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977, 62:707–714.CrossRefPubMedGoogle Scholar
  9. 9.
    Miller NE, Thelle DS, Forde OH, Mjos OD: The Tromso heart-study: high-density lipoproteins and coronary heart-disease: a prospective case-control study. Lancet 1977, 1:965–968.CrossRefPubMedGoogle Scholar
  10. 10.
    Glomset JA, Janssen ET, Kennedy R, et al: Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res 1966, 7:638–648.PubMedGoogle Scholar
  11. 11.
    Brewer HB Jr, Santamarina-Fojo S, Hoeg JM: The molecular biology of the human plasma apolipoproteinemia, lipoprotein receptors, and lipoprotein lipase. In Primary Hyperlipoproteinemias. Edited by Steiner G, Shafrir E. New York: McGraw-Hill; 1990:43–74.Google Scholar
  12. 12.
    Breslow JL: Familial disorders of high-density lipoprotein metabolism. In The Metabolic and Molecular Bases of Inherited Disease. Edited by Scriver CR, Beaudet AL, Sly WS, et al. New York: McGraw-Hill; 1995:2031–2052.Google Scholar
  13. 13.
    Menotti A, Keys A, Aravanis C, et al: Seven Countries Study. First 20-year mortality data in 12 cohorts of six countries. Ann Med 1989, 21:175–179.CrossRefPubMedGoogle Scholar
  14. 14.
    Keys A: High density lipoprotein cholesterol and longevity. J Epidemiol Community Health 1987, 42:60–65.CrossRefGoogle Scholar
  15. 15.
    Barter P, Gotto AM, LaRosa JC, et al: Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301–1310.CrossRefPubMedGoogle Scholar
  16. 16.
    Barter PJ, Baker PW, Rye KA: Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 2002,13:285–288.CrossRefPubMedGoogle Scholar
  17. 17.
    Mineo C, Shaul PW: Role of high-density lipoprotein and scavenger receptor B type I in the promotion of endothelial repair. Trends Cardiovasc Med 2007, 17:156–161.CrossRefPubMedGoogle Scholar
  18. 18.
    Marathe GK, Zimmerman GA, McIntyre TM: Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 2002, 278:3937–3947.CrossRefPubMedGoogle Scholar
  19. 19.
    Parthasarathy S, Fong LG, Otero D, Steinberg D: Recognition of solubilized apoproteins from delipidated, oxidized low density lipoprotein (LDL) by the acetyl-LDL receptor. Proc Natl Acad Sci U S A 1987, 84:537–540.CrossRefPubMedGoogle Scholar
  20. 20.
    Parthasarathy S, Barnett J, Fong LG: High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990, 1044:275–283.PubMedGoogle Scholar
  21. 21.
    Brewer HB Jr, Santamarina-Fojo S, Hoeg JM: Molecular biology of the lipoproteins and the apolipoproteins and their role in atherosclerosis. In Molecular Basis of Cardiology. Edited by Roberts R. Boston: Blackwell Scientific; 1992:415–441.Google Scholar
  22. 22.
    Segrest JP, Jones MK, De Loof H, et al: The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 1992, 33:141–166.PubMedGoogle Scholar
  23. 23.
    Segrest JP, Garber DW, Brouillette CG, et al: The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem 1994, 45:303–369.CrossRefPubMedGoogle Scholar
  24. 24.
    Brewer HB Jr, Remaley AT, Neufeld EB, et al: Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoproteins in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004, 24: 1755–1760.CrossRefPubMedGoogle Scholar
  25. 25.
    Acton S, Rigotti A, Landschulz KT, et al: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271:518–520.CrossRefPubMedGoogle Scholar
  26. 26.
    Murao K, Terpstra V, Green SR et al: Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem 1997, 272:17551–17557.CrossRefPubMedGoogle Scholar
  27. 27.
    Landschulz KT, Pathak RK, Rigotti A, et al: Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 1996, 98:984–995.CrossRefPubMedGoogle Scholar
  28. 28.
    Tall AR: Metabolic and genetic control of HDL cholesterol levels. J Intern Med 1992, 231:661–668.CrossRefPubMedGoogle Scholar
  29. 29.
    Assman G, von Eckardstein A, Brewer HB Jr: The Metabolic and Molecular Basis of Inherited Disease, edn 8. Edited by Scriver CR, Beaudet AL, Sly WS, et al. New York: McGraw Hill; 2001: 2937–2980.Google Scholar
  30. 30.
    Scanu AM, Fless GM: Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990, 85:1709–1715.CrossRefPubMedGoogle Scholar
  31. 31.
    Rader DJ, Schaefer JR, Lohse P, et al: Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism 1993, 42: 1429–1434.CrossRefPubMedGoogle Scholar
  32. 32.
    Ikewaki K, Rader DJ, Sakamoto T, et al: Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 1993, 92: 1650–1658.CrossRefPubMedGoogle Scholar
  33. 33.
    Tall AR: Plasma cholesteryl ester transfer protein. J Lipid Res 1993, 34:1255–1274.PubMedGoogle Scholar
  34. 34.
    Yamashita S, Ishigami M, Arai T, et al: Very high density lipoproteins induced by plasma cholesteryl ester transfer protein (CETP) have a potent antiatherogenic function. Ann N Y Acad Sci 1995, 748:606–608.CrossRefPubMedGoogle Scholar
  35. 35.
    Tall AR: An overview of reverse cholesterol transport. Eur Heart J 1998, 19:A31–A35.PubMedGoogle Scholar
  36. 36.
    Ng DS, Leiter LA, Vezina C, et al: Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest 1994, 93:223–229.CrossRefPubMedGoogle Scholar
  37. 37.
    Lackner KJ, Dieplinger H, Nowicka G, et al: High density lipoprotein deficiency with xanthomas. A defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene. J Clin Invest 1993, 92:2262–2273.CrossRefPubMedGoogle Scholar
  38. 38.
    Bekaert ED, Alaupovic P, Knight-Gibson CS, et al: Characterization of apo A- and apo B-containing lipoprotein particles in a variant of familial apo A-I deficiency with planar xanthoma: the metabolic significance of LP-A-II particles. J Lipid Res 1991, 32:1587–1599.PubMedGoogle Scholar
  39. 39.
    Sherman JL, Citrin C, Johns T, et al: Erdheim-Chester disease: ­computed tomography in two cases. Am J Neuroradiol 1985, 6:444–445.PubMedGoogle Scholar
  40. 40.
    Ordovas JM, Cassidy DK, Civeira F, et al: Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem 1989, 264:16339–16342.PubMedGoogle Scholar
  41. 41.
    Genest JJ Jr, Martin-Munley SS, McNamara JR, et al: Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992, 85:2025–2033.PubMedGoogle Scholar
  42. 42.
    Schaefer EJ, Blum CB, Levy RI, et al: Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N Engl J Med 1978, 299:905–910.CrossRefPubMedGoogle Scholar
  43. 43.
    Schaefer EJ, Zech LA, Schwartz DE, Brewer H Jr: Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann Intern Med 1980, 93:261–266.PubMedGoogle Scholar
  44. 44.
    Serfaty-Lacrosniere C, Civeira F, Lanzberg A, et al: Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994, 107:85–98.CrossRefPubMedGoogle Scholar
  45. 45.
    Rader DJ, Ikewaki K, Duverger N, et al: Very low high-density lipoproteins without coronary atherosclerosis. Lancet 1993, 342:1455–1458.CrossRefPubMedGoogle Scholar
  46. 46.
    Krauss RM: Regulation of high density lipoprotein levels. Med Clin North Am 1982, 66:403–430.PubMedGoogle Scholar
  47. 47.
    Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary artery disease in men with low levels of ­high-density lipoprotein cholesterol. Veterans Affairs High Density Lipoprotein Cholesterol Intervention Study Group. N Engl J Med 1999, 341:410–418.CrossRefPubMedGoogle Scholar
  48. 48.
    Brewer HB Jr: High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004, 24:387–391.CrossRefPubMedGoogle Scholar
  49. 49.
    Brewer HB Jr: Increasing HDL cholesterol levels. N Engl J Med 2004, 350:1491–1494.CrossRefPubMedGoogle Scholar
  50. 50.
    Nissen SE, Tsunoda T, Tuzcu EM, et al: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292–2300.CrossRefPubMedGoogle Scholar
  51. 51.
    Waksman R, Kent K, Pichard M, et al: A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated HDL plasma infusions in patients with acute coronary syndrome. Circulation 2008, 118:S371.Google Scholar
  52. 52.
    Barter PJ, Caulfield M, Eriksson M, et al: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.CrossRefPubMedGoogle Scholar
  53. 53.
    Cannon CP, Dansky HM, Davidson M, et al: Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J 2009, 158:513–519.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • H. Bryan BrewerJr
    • 1
  1. 1.Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, MedStar Research InstituteWashington Hospital CenterWashingtonUSA

Personalised recommendations